May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?

European Journal of Cardio-thoracic Surgery

Volumn 38, Issue 3, 2010, Pages 245-252

  Mineo, Tommaso Claudio ^a   Ambrogi, Vincenzo ^a   Cufari, Maria Elena ^a   Pompeo, Eugenio ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cyclooxygenase 2 (COX 2); Malignant pleural mesothelioma; P21; P27; Thoracic surgery

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN P21; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PLEURODESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 2; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PLEURAL NEOPLASMS; PNEUMONECTOMY; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77955919348     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.02.012     Document Type: Article

References (25)

1. Flores R.M., Rusch V.W. Diffuse malignant mesothelioma. General thoracic surgery 2005, 901-921. Lippincott Williams & Wilkins, Philadelphia. T. Shields (Ed.).
2. Sugarbaker D., Flores R., Jaklitsch M., Richards W., Strauss G., Corson J., DeCamp M., Swanson S., Bueno R., Lukanich J., Baldini E., Mentzer S. Resection margins, extrapleural nodal status and cell type determine postoperative long term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54-65.
3. Weder W., Stahel R.A., Bernhard J., Bodis S., Vogt P., Ballabeni P., Lardinois D., Betticher D., Schmid R., Stupp R., Ris H.B., Jermann M., Mingrone W., Roth A.D., Spiliopoulos A. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007, 18:1196-1202. Swiss Group for Clinical Cancer Research.
4. Grosch S., Tegeder I., Niederberger E., Bräutigam L., Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001, 15:2742-2744.
5. Uefuji K., Ichikura T., Mochizuki H. Cycloxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000, 6:135-138.
6. Sherr C.S. Cancer cell cycles. Science 1996, 274:1672-1677.
7. Kirsch D.G., Kastan M.B. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998, 16:3158-3168.
8. Rusch V.W. A proposed new international TNM-staging system for malignant pleural mesothelioma: International Mesothelioma Interest Group. Chest 1995, 108:1122-1128.
9. Baldi A., Santini D., Vasaturo F., Santini M., Vicidomini G., Di Marino M.P., Esposito V., Groeger A.M., Liuzzi G., Vincenzi B., Tonini G., Piccoli M., Baldi F., Scarpa S. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 2004, 59:428-433.
10. O'Kane S.L., Cawkwell L., Campbell A., Lind M.J. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma. Eur J Cancer 2005, 41:1645-1648.
11. Pilling J.E., Stewart D.J., Martin-Ucar A.E., Muller S., O'Byrne K.J., Waller D.A. The case of routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2004, 25:497-501.
12. O'Byrne K.J., Edwards J.G., Waller D.A. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer 2004, 455:S45-S48.
13. Edwards J.G., Faux S.P., Plummer S.M., Abrams K.R., Walker R.A., Waller D.A., O'Byrne K.J. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002, 8:1857-1862.
14. O'Kane S.L., Eagle G.L., Greenman J., Lind M.J., Cawkwell L. COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer 2010, 67(2):160-165.
15. Edwards J.G., Swinson D.E., Jones J.L., Waller D.A., O'Byrne K.J. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 2006, 54:399-407.
16. Pompeo E., Albonici L., Doldo E., Orlandi A., Manzari V., Modesti A., Mineo T.C. Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. Ann Thorac Surg 2009, 88:426-431.
17. Bongiovanni M., Cassoni P., De Giuli P., Viberti L., Cappia S., Ivaldi C., Chiusa L., Bussolati G. p27kip1 immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 2001, 92:1245-1250.
18. Baldi A., Groeger A.M., Esposito V., Cassandro R., Tonini G., Battista T., Di Marino M.P., Vincenzi B., Santini M., Angelini A., Rossiello R., Baldi F., Paggi M.G. Expression of p21 in SV40 large T antigen positive human pleural mesothelioma: relationship with survival. Thorax 2002, 57:353-356.
19. kip-1. J Biol Chem 2002, 277:9763-9771.
20. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., Gatzemeier U., Boyer M., Emri S., Manegold C., Niyikiza C., Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
21. Martin-Ucar A.E., Edwards J.G., Rengajaran A., Muller S., Waller D.A. Palliative surgical debulking in malignant mesothelioma: predictors of survival and symptom control. Eur J Cardiothorac Surg 2001, 120:1117-1121.
22. Ambrogi V., Mineo D., Gatti A., Pompeo E., Mineo T.C. Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma. J Surg Oncol 2009, 100:199-204.
23. Lee T.T., Everett D.L., Shu H.G., Jahan T.M., Roach M., Speight J.L., Cameron R.B., Phillips T.L., Chan A., Jablons D.M. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002, 124:1183-1189.
24. Luckraz H., Rahman M., Patel N., Szafranek A., Gibbs A.R., Butchart E.G. Three decades of experience the surgical multimodality management of pleural mesothelioma. Eur J Cardiothorac Surg 2010, 37(3):552-556.
25. Flores R.M., Akhurst T., Gonen M., Zakowski M., Dycoco J., Larson S.M., Rusch V.W. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006, 132:763-768.